Allergy Therapeutics (LON:AGY) Stock Price Down 13.7% – Here’s What Happened

Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price dropped 13.7% during mid-day trading on Thursday. The stock traded as low as GBX 1.21 and last traded at GBX 1.21. Approximately 8,691,818 shares changed hands during trading, an increase of 1,548% from the average session volume of 527,447 shares. The stock had previously closed at GBX 1.40.

Allergy Therapeutics Stock Performance

The stock has a market cap of £71.30 million, a price-to-earnings ratio of -1.16, a P/E/G ratio of -30.70 and a beta of 0.83. The company has a current ratio of 2.29, a quick ratio of 1.48 and a debt-to-equity ratio of -646.31. The firm has a fifty day simple moving average of GBX 3.73 and a 200-day simple moving average of GBX 7.33.

About Allergy Therapeutics

(Get Free Report)

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.

See Also

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.